(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Two Indonesian UN peacekeepers killed in explosion in Lebanon - 2Israel says 40 Hezbollah members killed as forces advance in Lebanon
- 3How to avoid or deal with an outrageous medical bill
- 4World’s tallest bridge and biggest museum named ‘greatest places of 2026’
- 5EU chief urges Iran to free imprisoned protesters, lift internet ban
- Uranus's small moons are dark, red, and water-poor
- Figuring out the Justification for Separation: To blame and No-Shortcoming
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- NASA counts down for first crewed lunar mission in half a century
- Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- Yoshi mania, Happy Meals and not-so-great reviews: A small talk guide to 'The Super Mario Galaxy Movie'
- Top 10 Smash hit Computer games of the Year
- Europe must reinvent warfare for ‘era of shocks,’ NATO’s Vandier says
- The Best 10 Innovation Advancements of the Year
